At all Walgreens locations, Alvesco will be available at no cost or reduced cost to eligible patients “Asthma is one of the country’s most common diseases, impacting 25 million individuals across the ...

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide ...

The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug. Alvesco was approved earlier ...

Switzerland-headquartered Nycomed has signed a deal worth potentially over $400 million with Sepracor which will see the latter firm gain the US rights to the corticosteroid ciclesonide.

Firm gains two approved products, the API, ciclesonide, and three line-extension programs. Nycomed granted Sepracor exclusive U.S. licenses to ciclesonide and two approved products containing this API ...

ZUG, Switzerland--(BUSINESS WIRE)--Covis Pharma B.V. (“Covis Pharma”), a global specialty pharmaceutical company, is pleased to announce an agreement with Walgreens, one of the largest drugstore ...

Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above LUXEMBOURG and ZUG, Switzerland, May 19, 2020 /CNW/ -- Covis Pharma B.V.

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 "We are committed to rapidly evaluating Alvesco as a ...